PMID- 22542658
OWN - NLM
STAT- MEDLINE
DCOM- 20120928
LR  - 20181201
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 685
IP  - 1-3
DP  - 2012 Jun 15
TI  - Effect of rosiglitazone on the expression of cardiac adiponectin receptors and 
      NADPH oxidase in type 2 diabetic rats.
PG  - 116-25
LID - 10.1016/j.ejphar.2012.04.010 [doi]
AB  - This study investigated the effect of rosiglitazone on the expression of cardiac 
      adiponectin receptors and NADPH oxidase in type 2 diabetic rats. Thirty-six male 
      Wistar rats were randomly divided into control (C, n=10), diabetic (D, n=13) and 
      diabetic treated with rosiglitazone (DT, n=13). Type 2 diabetes was induced by 
      high-fat and high-sugar diet and intraperitoneal injection of a low dose of 
      streptozotocin (STZ). Eleven rats in diabetic untreated group and twelve rats in 
      diabetic treated group were successfully induced to be diabetes. After induction 
      of diabetes, rosiglitazone (3mg/kg/day) was administrated to diabetic treated 
      rats by gavage for 12 weeks. Twelve weeks later, the heart function was detected. 
      Plasma and myocardial adiponectin levels were detected by enzyme linked 
      immunosorbent assay (ELISA). The cardiac mRNA expression of adiponectin receptors 
      1 and 2, and monocyte chemoattractant protein-1 (MCP-1) was assayed by reverse 
      transcript-polymerase chain reaction (RT-PCR). The cardiac mRNA expression of 
      p22phox and NOX4 was assayed by real-time fluorescence quantitative PCR. The 
      cardiac protein expression of phosphor-AMPK-alpha (Thr172) and glucose transporter 4 
      (GLUT4) was determined by Western blotting. The protein expression of adiponectin 
      receptors 1 and 2, and connective tissue growth factor (CTGF)were determined by 
      immunohistochemistrial staining. The ratio of heart weight to body weight was 
      significantly increased in diabetic rats compared to control. Heart function, 
      plasma and myocardial adiponectin levels, the protein and mRNA expression of 
      myocardial adiponectin receptors 1 and 2, myocardial phosphorylation of AMPK-alpha 
      (Thr172) and the protein expression of myocardial GLUT4 were significantly 
      decreased in diabetic rats compared to control (P<0.05). The expression of 
      myocardial p22phox, Nox4, MCP-1 and CTGF was significantly increased in diabetic 
      rats compared to control (P<0.05). Rosiglitazone treatment significantly 
      attenuated the increased ratio of heart weight to body weight, and the increased 
      expression of myocardial p22phox, Nox4, MCP-1 and CTGF in diabetic rats (P<0.05). 
      Heart function, plasma and myocardial adiponectin levels, the expression of 
      myocardial adiponectin receptors 1 and 2 and GLUT4, and myocardial 
      phosphorylation of AMPK-alpha (Thr172) were significantly decreased in diabetic 
      treated with rosiglitazone compared to diabetic untreated (P<0.05). These results 
      suggest that the protective effects of rosiglitazone on diabetic rat hearts may 
      be attributable to the increased myocardial adiponectin and its receptors and the 
      decreased myocardial NADPH oxidase.
CI  - Copyright (c) 2012 Elsevier B.V. All rights reserved.
FAU - Guo, Zhixin
AU  - Guo Z
AD  - Department of Endocrinology, Second Hospital, Shanxi Medical University, Taiyuan, 
      Shanxi, 030001, PR China. zhxguo1966@yahoo.com.cn
FAU - Qin, Zhihong
AU  - Qin Z
FAU - Zhang, Rong
AU  - Zhang R
FAU - Li, Jiawei
AU  - Li J
FAU - Yin, Yan
AU  - Yin Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120420
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Adiponectin)
RN  - 0 (Glucose Transporter Type 4)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Adiponectin)
RN  - 0 (Slc2a4 protein, rat)
RN  - 0 (Thiazolidinediones)
RN  - 0 (adiponectin receptor 1, rat)
RN  - 0 (adiponectin receptor 2, rat)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - 5W494URQ81 (Streptozocin)
RN  - EC 1.6.3.- (NADPH Oxidases)
SB  - IM
MH  - Adiponectin/metabolism
MH  - Animals
MH  - Diabetes Mellitus, Experimental/*drug therapy/physiopathology
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Gene Expression Regulation/drug effects
MH  - Glucose Transporter Type 4/genetics
MH  - Hypoglycemic Agents/*pharmacology
MH  - Male
MH  - Myocardium/metabolism
MH  - NADPH Oxidases/genetics/metabolism
MH  - Phosphorylation/drug effects
MH  - RNA, Messenger/metabolism
MH  - Random Allocation
MH  - Rats
MH  - Rats, Wistar
MH  - Receptors, Adiponectin/genetics/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Rosiglitazone
MH  - Streptozocin
MH  - Thiazolidinediones/*pharmacology
EDAT- 2012/05/01 06:00
MHDA- 2012/09/29 06:00
CRDT- 2012/05/01 06:00
PHST- 2011/12/17 00:00 [received]
PHST- 2012/04/01 00:00 [revised]
PHST- 2012/04/05 00:00 [accepted]
PHST- 2012/05/01 06:00 [entrez]
PHST- 2012/05/01 06:00 [pubmed]
PHST- 2012/09/29 06:00 [medline]
AID - S0014-2999(12)00344-5 [pii]
AID - 10.1016/j.ejphar.2012.04.010 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2012 Jun 15;685(1-3):116-25. doi: 10.1016/j.ejphar.2012.04.010. 
      Epub 2012 Apr 20.